Address: Avenida Ayrton Senna, 1850 Loja 118 – Barra Da Tijuca CEP: 22775-001 Rio De Janeiro RJ,Brazil
Tel: 21 24303183
Web: http://www.octapharma.com.br/
Octapharma is an independent, Swiss-based company founded in 1983 by Mr. Wolfgang Marguerre.
Octapharma’s core business is the development, production and sale of safe and effective medicines derived from human proteins in the following areas: Haematology (coagulation disorders), Immunotherapy (immune disorders), Intensive Care and Emergency Medicine
Octapharma has since grown to include six state-of-the-art production plants in Austria, France, Germany, Sweden and Mexico, 54 Plasma Donation Centres in the US and in Europe as well as 37 subsidiaries and representative offices. With over 4,000 employees, Octapharma currently makes sales in over 80 countries.
Turnover in 2009 broke the €1 billion mark, and Octapharma continues to grow and invest heaviliy in the future. Profits are mainly channelled into R&D and further production improvements and expansion.
octagam, rhesonativ, octanate, gammanorm, albunorm, albuminativ
Samuel Mauricio, vice-president for Brazil at Octapharma, one of the largest human protein manufacturers in the world, provides an insightful analysis of the Brazilian plasma market, demonstrating Octapharma’s remarkable willingness…
Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could…
An overview of some of the biggest stories from Latin American pharma and healthcare, including Brazil’s rollout of dengue vaccines following a sharp increase in cases; the Brazilian regulatory agency…
A roundup of some of the latest stories from Latin American pharma and healthcare, including Sanfer’s acquisition of Columbia-based injectables manufacturer Vitalis; medicine shortages in Colombia, and Chile’s move towards…
Brazil’s ANVISA is commonly recognised as LatAm’s leading national medicines regulator and is defined by the Pan American Health Organization (PAHO) as a National Regulatory Authority of Regional Reference (NRAr) for medicines…
The latest pharma news from Brazil, including the partnership between Biophytis and Innovation Solutions Pharma; Merck’s 100 years in Brazil; Eurofarma’s USD 100 million biotech investment, and GSK’s green light…
A roundup of some of the latest news from Latin American pharma, including Acino’s acquisition of M8 Pharmaceuticals; AstraZeneca’s growth in Mexico; Neuraxpharm’s expansion into Brazil and Mexico, and Columbia’s…
The DIA Global Annual Meeting 2023 hosted DIA’s first regulatory Town Hall fully dedicated to one regulator from Latin America, as leadership from Brazil’s Health Regulatory Agency, ANVISA, shared updates on the…
The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on…
A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences…
Having spent 25 years in the rare disease arena, Maria Gabriella Pittis now finds herself at the forefront of a different field, spearheading the launch of Takeda’s dengue vaccine across…
As the COVID-19 pandemic showed, vaccines are humanity’s best weapon in the fight against infectious diseases. Nowhere is this more evident than Latin America, where specific climatic, geographic, and social…
Henrique Tada of ALANAC, the association that brings together Brazil’s domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories’ internationalisation efforts,…
In a wide-ranging interview, AbbVie’s Flavio Devoto outlines some of the key access challenges and opportunities in the diverse Latin American pharma market, his approach to being a transformational leader…
See our Cookie Privacy Policy Here
